Past Issues

Platelet-Rich Plasma Therapy for Telogen Effluvium: A Comprehensive Evaluation of Efficacy and Safety

Uzma Dost Muhammad Rajar1*, Amin Fahim2, Sumayya Qazi3, Navaid Kazi4, Neeta Maheshwary5, Arjumand Ahmed- Rph6

1Department of Dermatology, Isra University Hyderabad, Pakistan

2Department of Pathology, People's University of Medical and Health Sciences for women, Isra University, Hyderabad, Pakistan

3Department of Biochemistry, Isra University Hyderabad, Pakistan

4Department of Physiology, Isra University Hyderabad, Pakistan

5Head of Medical Affairs, Helix Pharma, Karachi, Pakistan

6Medical Affairs, Helix Pharma, Karachi, Pakistan

*Corresponding Author: Uzma Dost Muhammad Rajar, Department of Dermatology, Isra University Hyderabad, Pakistan; Email: [email protected]

Received Date: February 26, 2024

Publication Date: March 20, 2024

Citation: Rajar UDM, et al. (2024). Platelet-Rich Plasma Therapy for Telogen Effluvium: A Comprehensive Evaluation of Efficacy and Safety. Dermis. 4(1):9.

Copyright : Rajar UDM, et al. © (2024).


Background: Chronic Telogen Effluvium (TE) is a common hair loss condition. This study explores the effectiveness of PRP and Tressfix Serum in treating Chronic TE. It aims to uncover potential therapeutic approaches through microRNA expression analysis. Objective: The objective is to evaluate the effectiveness and safety of combining platelet-rich plasma (PRP) with Tressfix Serum in treating chronic TE and to evaluate the impact on microRNA expression related to this condition. Methods: Patients including both male and females of aged between 20-40 years diagnosed with TE were included. Patients with scalp-specific dermatological illnesses, such as psoriasis or seborrheic dermatitis, were excluded. PRP was prepared using a double spin process and injected intradermally at designated scalp sites. Patients underwent a total of seven treatment sessions over a 14-week period Results: The study demonstrated a significant improvement in hair regrowth and reduction in hair shedding among participants following PRP therapy. All miRNA expression was significantly reduced in group A and group B where as in group C five out of nine miRNA expresses no significant p>0.05 mean difference. The expression levels of hsa-mir-223 were considerably lower in Group A (PRP and Tressfix serum combined) (113.53±2.95) compared to Group B (PRP alone, 140.21±5.56) and Group C (Tressfix serum alone, 163.22±2.37). The expression of hsa-mir-212 was also less in Group A (53.5±7.56) than in Group B (75.58±8.71) and Group C (87.12±6.9). These variations in expression imply that the combination strategy of PRP and Tressfix serum may have a more significant impact on lowering microRNA expression linked to TE than either therapy alone. Conclusion: The study underscores the importance of patient selection criteria and meticulous technique in optimizing treatment outcomes. Further research is warranted to elucidate the long-term efficacy and durability of PRP therapy in TE management.

Keywords: MicroRNAs, Platelet-Rich Plasma (PRP), Scalp, Telogen effluvium (TE), SALT scale

Suggested For You
Creative Commons License

Open Access by Magnus Med Club Ltd is licensed under a Creative Commons Attribution 4.0 International License. Based On a Work at

©2018 Magnus Med Club Ltd. All rights Reserved. Dermis is an Independent Peer-Reviewed Dermatology Journal. Terms of ServicePrivacy Policy